PARP Inhibitors for the Treatment of BRCA1/ 2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis
Background: The PARP inhibitors (PARPis) olaparib and talazoparib are currently approved for the treatment of deleterious germline BRCA1/2-mutated (gBRCA+) metastatic breast cancer (MBC). These approvals were based on improvements in progression-free survival (PFS) observed in two randomized control...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wolters Kluwer Medknow Publications
2023-07-01
|
| Seri Bilgileri: | Hematology/Oncology and Stem Cell Therapy |
| Konular: | |
| Online Erişim: | https://journals.lww.com/10.56875/2589-0646.1033 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|